Table 4. . Baseline characteristics by stage and measurable disease at time of treatment.
| Clinical feature | Recurrent stage 3 (n = 18) | Nonmeasurable stage 4 (n = 30) | Measurable stage 4 (n = 24) | All (n = 72) |
|---|---|---|---|---|
| Age >60 years (median 52 years) | 4 (22%) | 6 (20%) | 9 (38%) | 19 (26%) |
| Proportion male | 9 (50%) | 21 (70%) | 15 (62%) | 45 (62%) |
| Unknown primary | 1 (6%) | 7 (23%) | 7 (29%) | 15 (21%) |
| Acrolentiginous primary | 1 (6%) | 2 (7%) | 1 (4%) | 4 (6%) |
| Ocular primary | 0 | 1 (3%) | 1 (4%) | 2 (3%) |
| Mucosal primary | 0 | 0 | 0 | 0 |
| Stage 3 at time of tumor collection | 17 (100%) | 2 (7%) | 9 (42%) | 29 (40%) |
| Stage 4 at time of tumor collection | 0 | 28 (93%) | 15 (62%) | 43 (60%) |
| Lymph node source of tissue | 14 (78%) | 7 (23%) | 11 (46%) | 32 (44%) |
| Soft tissue source of tissue | 4 (22%) | 9 (30%) | 8 (33%) | 17 (24%) |
| Lung source of tissue | – | 5 (17%) | 2 (8%) | 7 (10%) |
| Visceral met (not lung) | – | 9 (30%) | 3 (12%) | 14 (19%) |
| Ave number prior therapies | 3.0 | 3.3 | 3.9 | 3.4 |
| Prior lymph node and/or soft tissue metastases | 18 (100%) | 16 (53%) | 21 (88%) | 55 (76%) |
| Prior lung metastases | – | 8 (27%) | 7 (29%) | 20 (28%) |
| Prior breast metastases | – | 2 (7%) | 2 (8%) | 4 (6%) |
| Prior bone metastases | – | 2 (7%) | 2 (7%) | 4 (6%) |
| Prior gallbladder metastases | – | 0 | 1 (4%) | 1 (1%) |
| Prior adrenal metastases | – | 1 (3%) | 1 (4%) | 2 (3%) |
| Prior bowel metastases | – | 3 (10%) | 4 (17%) | 7 (10%) |
| Prior splenic metastases | – | 4 (13%) | 1 (4%) | 5 (7%) |
| Prior liver metastases | – | 7 (23%) | 3 (12%) | 10 (14%) |
| Prior brain metastases | – | 6 (20%) | 8 (33%) | 14 (19%) |
| ECOG 0 or KPS 100 | 17 (94%) | 23 (77%) | 7 (29%) | 47 (65%) |
| Elevated LDH at treatment | 3 (17%) | 7 (23%) | 13 (54%) | 23 (32%) |
| Anergic to common skin tests | 3 (17%) | 11 (37%) | 3 (17%) | 17 (24%) |
| Tumor DTH positive at baseline | 0 | 2 (7%) | 1 (4%) | 3 (4%) |
| Tumor DTH positive after vaccine | 3 (17%) | 8 (27%) | 2 (8%) | 13 (18%) |
DTH: Delayed type hypersensitivity test; ECOG: Eastern Cooperative Oncology Group; Mets: Metastasis; KPS: Karnofsky Performance Status; NED: No evidence of disease; RT: Radiation therapy.